Literature DB >> 12504691

Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema.

Teiko Yamamoto1, Koichiro Hitani, Itsuro Tsukahara, Shuichi Yamamoto, Ryo Kawasaki, Hidetoshi Yamashita, Shinobu Takeuchi.   

Abstract

PURPOSE: To determine the early postoperative changes in retinal thickness and complications after pars plana vitrectomy for diabetic macular edema.
DESIGN: Consecutive interventional case series.
METHODS: Studied retrospectively, pars plana vitrectomy was performed on 65 consecutive eyes of 63 patients with diabetic macular edema. The follow-up interval ranged from 6 to 36 months (12.6 +/- 7.4 months [mean +/- standard deviation (SD)]). The indications of pars plana vitrectomy in this study were (1) diffuse diabetic macular edema, (2) preoperative visual acuity less than 20/40, and (3) noneffective macular photocoagulation therapy. Preoperative and postoperative examinations by stereoscopic biomicroscopy, color fundus photography of the macula and optical coherence tomography (OCT) were performed on all eyes. Preoperatively, direct photocoagulation to microaneurysms in the macula had been performed in 48 eyes, and focal/grid photocoagulation had been performed in five eyes. Preoperative examination showed that epiretinal membranes were observed in 20 eyes, cystoid macular edema in 40 eyes, and 23 eyes had a complete posterior vitreous detachment (PVD). Epimacular membranes, removed during surgery, were examined histopathologically.
RESULTS: The postoperative mean best-corrected visual acuity (logarithm of the minimum angle of resolution [logMAR] = 0.696 +/- 0.491 [mean +/- SD]) was significantly better than the preoperative mean best-corrected visual acuity (0.827 +/- 0.361; P <.0001; Wilcoxon signed-rank test). The final visual acuity improved by 2 or more lines in 32 of 65 eyes (45%), remained unchanged in 32 of 65 eyes (49%), and exacerbated after the surgery in 4 of 65 eyes (6%) due to neovascular glaucoma (2 eyes) and residual cystoid macular edema (2 eyes). The postoperative foveal retinal thickness (224.9 +/- 116.9 microm) at the last visit was significantly thinner than the preoperative foveal retinal thickness (463.7 +/- 177.3 microm; P <.0001; Wilcoxon signed-rank test). The foveal retinal thickness did not decrease linearly but fluctuated: The mean postoperative retinal thickness had decreased significantly 7 days after surgery, then remained unchanged for approximately 1 month, and thereafter gradually decreased until 4 months. The intraoperative and postoperative complications included peripheral retinal tear in 3 of 65 (4.6%) eyes, postoperative rhegmatogenous retinal detachment in 1 of 65 (1.5%) eyes, neovascular glaucoma in 3 of 65 (5%) eyes, recurrent vitreous hemorrhage in 1 of 65 (1.5%) eyes, hard exudates in the center of the macula in 3 of 56 (4.6%) eyes, postoperative epiretinal membrane formation in 9 of 65 (13.8%) eyes, and a lamellar macular hole in 1 of 65 (1.5%) eyes.
CONCLUSIONS: Vitrectomy for diabetic macular edema is an effective procedure for reducing the edema and improving visual acuity. Because the postoperative reduction in retinal thickness is not complete until 4 months, the assessment of vitrectomy on foveal thickness should not be made until this time. In addition, there are severe complications from vitrectomy for diabetic macular edema, and careful preoperative and postoperative examinations and surgical methods are required.

Entities:  

Mesh:

Year:  2003        PMID: 12504691     DOI: 10.1016/s0002-9394(02)01819-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  39 in total

1.  Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results.

Authors:  Yun Taek Kim; Se Woong Kang; Sang Jin Kim; Sung Min Kim; Song Ee Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-10       Impact factor: 3.117

2.  Macular ischemia and outcome of vitrectomy for diabetic macular edema.

Authors:  Jaeryung Kim; Se Woong Kang; Dong Hoon Shin; Sang Jin Kim; Ga Eun Cho
Journal:  Jpn J Ophthalmol       Date:  2015-08-01       Impact factor: 2.447

3.  Morphological and functional changes of the macula after vitrectomy and creation of posterior vitreous detachment in eyes with diabetic macular edema.

Authors:  Shuichi Yamamoto; Teiko Yamamoto; Kazuha Ogata; Akiko Hoshino; Eiju Sato; Satoshi Mizunoya
Journal:  Doc Ophthalmol       Date:  2004-11       Impact factor: 2.379

4.  Perifoveal vitreous detachment and its macular complications.

Authors:  Mark W Johnson
Journal:  Trans Am Ophthalmol Soc       Date:  2005

5.  Cystoid puncture for chronic cystoid macular oedema.

Authors:  Rishi P Singh; Ronald Margolis; Peter K Kaiser
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

6.  A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema.

Authors:  D Thomas; C Bunce; C Moorman; D A H Laidlaw
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

7.  Long-term follow-up results of pars plana vitrectomy for diabetic macular edema.

Authors:  Teiko Yamamoto; Shinobu Takeuchi; Yukihiro Sato; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

8.  Three-dimensional imaging of the inner limiting membrane folding on the vitreomacular interface in diabetic macular edema.

Authors:  Sachi Abe; Teiko Yamamoto; Yoshiko Kashiwagi; Eriko Kirii; Sakiko Goto; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2013-10-11       Impact factor: 2.447

9.  Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study.

Authors:  S P Shah; M Patel; D Thomas; S Aldington; D A H Laidlaw
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

Review 10.  Management of diabetic macular edema in Japan: a review and expert opinion.

Authors:  Hiroko Terasaki; Yuichiro Ogura; Shigehiko Kitano; Taiji Sakamoto; Toshinori Murata; Akito Hirakata; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2017-12-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.